Literature DB >> 21510734

Vascular abnormalities in human newborns with pulmonary hypertension.

Ilona Sluiter1, Irwin Reiss, Ulrike Kraemer, Ronald de Krijger, Dick Tibboel, Robbert J Rottier.   

Abstract

Pulmonary vascular disease embodies all congenital or acquired pathologies that affect the pulmonary vasculature. One of them is pulmonary hypertension of the newborn (PHN), which is clinically characterized by a persistent high pulmonary vascular resistance postnatally and an abnormal vascular response. Morphologically, the vascular walls of the small pulmonary arteries become thickened, leading to increased resistance of these vessels and thus a worsening of gas exchange. PHN occurs as a primary disease or in association with abnormal lung development, for example as in congenital diaphragmatic hernia, and is a critical determinant of morbidity and mortality. Here we review the current knowledge about vascular abnormalities in PHN and discuss the vascular abnormalities in different conditions associated with pulmonary hypertension in human newborns in relation to recent findings from molecular biology.

Entities:  

Mesh:

Year:  2011        PMID: 21510734     DOI: 10.1586/ers.11.8

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  9 in total

1.  The isolation and culture of endothelial colony-forming cells from human and rat lungs.

Authors:  Rajesh S Alphonse; Arul Vadivel; Shumei Zhong; Shumei Zong; Suzanne McConaghy; Robin Ohls; Mervin C Yoder; Bernard Thébaud
Journal:  Nat Protoc       Date:  2015-10-08       Impact factor: 13.491

2.  Quantitative pulmonary perfusion imaging at 3.0 T of 2-year-old children after congenital diaphragmatic hernia repair: initial results.

Authors:  F G Zöllner; K Zahn; T Schaible; S O Schoenberg; L R Schad; K W Neff
Journal:  Eur Radiol       Date:  2012-06-13       Impact factor: 5.315

3.  The Microcirculation Is Unchanged in Neonates with Severe Respiratory Failure after the Initiation of ECMO Treatment.

Authors:  Anke P C Top; Erik A B Buijs; Patrick H M Schouwenberg; Monique van Dijk; Dick Tibboel; Can Ince
Journal:  Crit Care Res Pract       Date:  2012-05-23

4.  Altered expression of PPAR‑γ and TRPC in neonatal rats with persistent pulmonary hypertension.

Authors:  Yanna Du; Jianhua Fu; Li Yao; Lin Qiao; Na Liu; Yujiao Xing; Xindong Xue
Journal:  Mol Med Rep       Date:  2017-06-09       Impact factor: 2.952

5.  Lung function in school-aged congenital diaphragmatic hernia patients; a longitudinal evaluation.

Authors:  Leontien C C Toussaint-Duyster; Monique H M van der Cammen-van Zijp; Marjolein Spoel; Harm A W M Tiddens; Dick Tibboel; Rene M H Wijnen; Joost van Rosmalen; Hanneke IJsselstijn
Journal:  Pediatr Pulmonol       Date:  2019-06-13

6.  A proteome signature of umbilical cord serum associated with congenital diaphragmatic hernia.

Authors:  Asuka Tachi; Yoshinori Moriyama; Hiroyuki Tsuda; Rika Miki; Takafumi Ushida; Mayo Miura; Yumiko Ito; Kenji Imai; Tomoko Nakano-Kobayashi; Masahiro Hayakawa; Fumitaka Kikkawa; Tomomi Kotani
Journal:  Nagoya J Med Sci       Date:  2020-05       Impact factor: 1.131

7.  Changes in vasoactive pathways in congenital diaphragmatic hernia associated pulmonary hypertension explain unresponsiveness to pharmacotherapy.

Authors:  Daphne S Mous; Marjon J Buscop-van Kempen; Rene M H Wijnen; Dick Tibboel; Robbert J Rottier
Journal:  Respir Res       Date:  2017-11-07

8.  Upregulated EFNB2 and EPHB4 promotes lung development in a nitrofen-induced congenital diaphragmatic hernia rat model.

Authors:  Hao Liu; Xue Li; Wen Qian Yu; Cai Xia Liu
Journal:  Int J Mol Med       Date:  2018-08-14       Impact factor: 4.101

9.  Impacts of Respiratory Muscle Training on Respiratory Functions, Maximal Exercise Capacity, Functional Performance, and Quality of Life in School-Aged Children with Postoperative Congenital Diaphragmatic Hernia.

Authors:  Samah A Moawd; Alshimaa R Azab; Zizi M Ibrahim; Anju Verma; Walid Kamal Abdelbasset
Journal:  Dis Markers       Date:  2020-09-04       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.